Challenges and opportunities for the next generation of clinicians.

As we covered in our longevity investment boom article, capital is flowing into the field at a rapidly growing rate.

But venture capital confidence is not equivalent to a clinician deciding if a field deserves an investment in education. So we set valuations aside and ask clinicians. Is exploring longevity medicine worth your time? 

The TL;DR 

Challenges are real:

• Uneven evidence. Much of what is sold under the longevity banner, from supplements to biomarker protocols, rests on thin data rather than large trials.
• Pull toward overtreatment. Do we risk turning healthy people into patients?
• Economics. Will longevity become a treatment just for the rich?

Yet the need is global:

• People are living longer without living better, a global gap of 9.6 years between lifespan and healthspan that someone has to close.
• Capital agrees it will last. Investment more than doubled in 2024 to roughly $8.5 billion.

The exact shape of longevity medicine is still forming, which is why it needs talented, focused experts from across disciplines to ensure its successful future. Read on for the full case and some honest caveats.

Precedents for Pessimism

We have seen ideas arrive as the future of medicine and then quietly, or not so quietly, disappear, from promising protocols that failed to replicate at scale, to models that aimed to reinvent healthcare but instead drifted until their credibility thinned.

So when longevity medicine arrives with confident talk of healthspan improvements, a fair question is whether it will still be standing in ten years. Does longevity and regenerative medicine have longevity as a field?

There are reasons to be optimistic, but they must balanced against the drawbacks of a novel field promising treatments not yet proven at scale.

Challenges of a novel field

Longevity medicine is still in its infancy as a discipline, and that stage carries risks any serious clinician needs to weigh. We take a look at five challenges that must be overcome.

The first is reputational. Longevity medicine still lives in the shadow of hype. A clinician who leans too hard into the language of breakthrough, optimisation and anti-ageing will lose credibility if evidence does not keep pace. Much of what is sold under the longevity banner, such as certain supplements, off-label prescribing and some biomarker-driven protocols, rests on early or thin data rather than large randomised trials.

This is underscored by controversies around supplements in the field. Resveratrol, the compound that helped launch the modern longevity boom, spent years struggling with replication problems and a failed pharmaceutical programme. The US National Institute on Aging's rigorous Interventions Testing Program identified real winners, but they tend to be prescription drugs like rapamycin and acarbose, not the supplements on sale. For example, fisetin, a popular senolytic, did not show a benefit in those studies. By contrast, NMN reliably raises NAD+ levels but has not yet been shown to extend human lifespan. Every overclaim that fails lowers the field's credibility.

The second is clinical, and it is the risk of overtreatment. Give a clinician a full toolkit of tests, biomarkers and therapies, and the temptation is to use all of it. Every marker slightly out of range becomes something to correct, every scan a reason to act, until a healthy person is being treated for problems that might never have mattered.

The whole point of longevity medicine is to give people more good years, yet overtreatment can quietly take those years back. Nobody wants a longer life spent in waiting rooms, on more medications, or managing their health every week instead of living it. Intrusive intervention works against the very thing longevity medicine exists to deliver, better and happier years of life.

The third is ethical, and it is the question of equality. As the epidemiologist Sir Michael Marmot has shown, health is shaped by the conditions in which people are born, grow, live, work and age. If, as now, most longevity care remains self-pay, it will be easiest to access for people who already have money, time and the habit of navigating the system. That can turn healthspan into a premium good and deepen the inequalities medicine is meant to reduce.

The fourth is the learning demand. This is not a specialty requiring constant learning, judgement and humility. The clinician who enters it has to be willing to stay a student for a long time, perhaps forever.

The fifth is operational and regulatory.  Longevity clinics often sit in a blurred space between medicine, wellness and commercial innovation, where boundaries are hard to hold and governance is thin. That creates exposure around claims, compliance and the basic question of where legitimate prevention ends and speculation begins. There is no agreed definition of longevity medicine, no single recognised standard of care, no established accreditation a patient can check, and little meaningful regulation of what a clinic may claim or sell.

In any mature specialty, decades of precedent, professional bodies, licensing requirements and defined guidelines hold practitioners to a common line. In longevity medicine, much of that scaffolding is missing, leaving the field open to its worst actors.

Every clinic overselling an unproven therapy, every protocol marketed ahead of its evidence, borrows against the credibility of everyone else in the space. Without shared standards, the responsible practitioner and the opportunist are hard for a patient to tell apart, and the whole field bears the cost.

The case for durability

Despite the risks, there is an overwhelming force behind longevity medicine's long-term durability: demographic change, and the burden of an ageing world.

The World Health Organization projects that by 2030 one in six people on earth will be aged 60 or over, with the over-60 population doubling to 2.1 billion by 2050. The number of people aged 80 and above will triple in the same period, reaching 426 million.

Noncommunicable diseases, the slow chronic conditions that fill a longevity practice, already account for roughly 74 percent of deaths worldwide.

A field built around delaying and managing that burden is not going away.

There is also a sign that the governance gap is beginning to close. In June 2026, Dubai established the Dubai Longevity Authority, the first regulator of its kind, tasked with building a science-led, risk-proportionate framework for longevity therapies and with licensing the whole chain from research and clinical trials through to patient clinics.

It is one government's answer to exactly the problem raised above, a field whose scientific promise has been running ahead of the rules meant to hold it to account. One authority in one city does not settle the question for the field as a whole, but it shows the direction of travel, and it signals that longevity medicine is being taken seriously enough to regulate.

A clinical problem worth solving

People are living longer without living better. A 2024 Mayo Clinic study in JAMA Network Open, drawing on data from 183 countries, found that the gap between lifespan and healthspan had widened to 9.6 years globally.

In the United States, it reaches 12.4 years; in the United Kingdom, 11.3. That is close to a decade of life spent burdened by disease, and the gap is widening, not narrowing.

Closing it is one of the most concrete clinical problems of the century, and it is exactly the problem longevity medicine is trying to address.

Why learning pays

Committing to training in longevity and regenerative medicine takes time and money, and that investment has to justify itself.

The strongest case is that the training compounds the authority you already have. A serious longevity education sharpens diagnostics, longitudinal thinking and the focus on function that good medicine already rewards.

It also moves expertise into a field where very few clinicians are yet fluent. Longevity medicine is still short of formally trained practitioners and still building its accreditation pathways, which means the doctors doing the work now will help set the standards that follow.

The field also has multiple entry points. Clinicians moving into longevity medicine often come from family medicine, internal medicine, endocrinology, sports medicine and rehabilitation, alongside researchers, pharmacists and nutrition specialists. What they share is a preference for preventive, longitudinal care over acute, episodic medicine.

New revenue models matter too. Early clinic models suggest longevity practice often runs on long-term patient relationships, self-pay or membership structures rather than insurance reimbursement, which can mean recurring revenue and a degree of clinical autonomy. That same model also sharpens the equality problem, since the people most drawn to prevention are often those with the means to pay for it.

Capital appears to agree that the market has legs. Investment in longevity companies more than doubled in 2024 to roughly $8.5 billion, up from $3.8 billion the year before. Capital at that scale usually follows sectors it expects to persist.

The global return

The most valuable part of longevity medicine is also the most misunderstood. People hear it and picture extra years bolted onto the end of life, more time spent old and unwell.

The real prize is the opposite. Longevity medicine is about improving healthspan, the years lived in good health, and that should not be a fringe ambition. It goes to the heart of what medicine is supposed to do.

The McKinsey Global Institute estimates that better population health could add around ten healthy years to midlife and unlock trillions in economic value.

Ethical purpose and financial incentive converge here, which is why the case for longevity medicine is becoming harder to ignore.

Why experts matter

So, does longevity medicine have a future as a field, and is it worth a clinician's attention?

On balance, yes. The field is necessary. The world is ageing, the gap between living long and living well is widening, and a discipline built to address that gap will not run short of purpose.

What is not yet settled is its shape. The standards, the practices and the boundaries are still being drawn. That is the risk. It is also the opportunity, because the clinicians who enter while the field is still forming are the ones who will help draw those lines, rather than inherit them.

For four days in Dubai, the people doing that work gather at Next Generation Medicine to present research, run workshops and argue through hard cases in public. Training pathways are represented too, including the Geneva College of Longevity Science, one of the first higher-education institutions dedicated to the field.

If you are still deciding whether longevity medicine is for you, it is one of the few places to test that against the real thing, the evidence, the practitioners, the honest disagreements. And if you have already decided, it is where you meet the people you will be working alongside for the next decade.

Next Generation Medicine 2026.
7 to 10 November. Atlantis The Royal, Dubai.
Get Tickets.